Soleno Therapeutics (SLNO) Other Accumulated Expenses (2018 - 2026)

Soleno Therapeutics (SLNO) has 9 years of Other Accumulated Expenses data on file, last reported at $24.9 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $24.9 million, up 697.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.9 million (up 697.28% YoY), and the FY2025 annual result was $18.2 million, up 298.82% from the prior year.
• Other Accumulated Expenses improved to $24.9 million in Q1 2026 per SLNO's latest filing, from $18.2 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $24.9 million in Q1 2026 and troughed at $415000.0 in Q2 2022.
• A 5-year average of $5.0 million and a median of $1.5 million in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2026: Other Accumulated Expenses rose 23.61% in 2023, then jumped 697.28% in 2026.
• A 5-year view of Other Accumulated Expenses shows it stood at $484000.0 in 2022, then surged by 221.28% to $1.6 million in 2023, then soared by 193.44% to $4.6 million in 2024, then soared by 298.82% to $18.2 million in 2025, then jumped by 37.0% to $24.9 million in 2026.
• Business Quant data shows SLNO's Other Accumulated Expenses at $24.9 million in Q1 2026, $18.2 million in Q4 2025, and $17.2 million in Q3 2025.